An observational study in Dermatitis, sponsored by Kimberly-Clark Corporation. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-11-01.
Sponsored by Kimberly-Clark Corporation · Observational
Among 110 studies in Dermatitis with a site in United States — 11 open to participants now, 20 under way, 7 of them phase 3. Dermatitis · United States.
Among the 110 studies in Dermatitis with a site in United States, this one is one of 4 that started in 2017, is one of 10 observational ones, and was the 45th registered.
238 studies on the registry are indexed under Dermatitis; 34 are open to participants now.
This study's enrollment of 10 is below the median of 183 across 35 observational studies indexed under Dermatitis.
Browse Dermatitis studies →11 of the 110 studies in Dermatitis with a site in United States are open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Dermatitis studies recruiting now, 11 (48%) set no upper age limit and 9 (39%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 40 Years · female.
The full table on the hub →110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 28 · Phase 4 9
First in 1976; this study’s year is marked. 4 started in 2017.
Median enrollment 49 across the 100 interventional studies, 26 across the 9 observational. Of the 81 that completed or were terminated, 39 (48%) have results posted.
68 of 110 have an industry lead sponsor. The 10 most frequent:
Kimberly-Clark Corporation is the lead sponsor of 16 studies on the registry; none are open to participants now.
Kimberly-Clark Corporation has 4 studies filed under Dermatitis — fewer than ten, so there is no comparison to draw.
6 of the studies in Dermatitis with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05535738Phase 3Wei-Che KoUsing a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation | 2027-01-01 |
| NCT06807268Phase 3PfizerA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | 2027-05-02 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT01631617National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Effects of Treatments on Atopic Dermatitis | 2027-01-01 |
Among the 110 studies in Dermatitis with a site in United States, from their registry updates:
This is a single-center, exploratory comparative pilot study to identify the most appropriate method for microbial consortia sampling from the skin.
Ten subjects are expected to complete the study at one investigative site in the United States.
The study will consist of 2 visits, Visit 1 (Screening), Visit 2 (Sampling). At Visit 1, subjects will be consented and have their eligibility reviewed. Visit 1 and Visit 2 may be combined into one visit. Visit 1 will involve the informed consent process, screening, and enrollment. Visit 2 will involve sampling of eight (8) test sites on the back with three (3) different sampling methods: swabbing (2 sites/method), cup scrub (2 sites/method), and tape stripping (4 sites/method). All samples will be returned to Kimberly Clark then sent to a laboratory for analysis.
Subjects will consist of ten (10)Caucasian female adults 18-40 years of age, at 1 US site.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Best method for collecting skin microbiome samples
Composition of skin microbiome by 16SrRNA pyrosequencing from 3 skin collection methods: Swabbing; Cup Scrub; and Tape Stripping
Time frame: 1 day
Plan to share: No — Subjects will be identified on logs and other documents submitted to the Sponsor by their unique identification number with or without their initials, not by name. Documents that identify the subject (e.g., the signed informed consent) are not to be submitted to the Sponsor and must be maintained in confidence by the Investigator.
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Aug 2017, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kimberly-Clark Corporation